[go: up one dir, main page]

PE20070221A1 - Inhibidores macrociclicos del virus de la hepatitis c - Google Patents

Inhibidores macrociclicos del virus de la hepatitis c

Info

Publication number
PE20070221A1
PE20070221A1 PE2006000917A PE2006000917A PE20070221A1 PE 20070221 A1 PE20070221 A1 PE 20070221A1 PE 2006000917 A PE2006000917 A PE 2006000917A PE 2006000917 A PE2006000917 A PE 2006000917A PE 20070221 A1 PE20070221 A1 PE 20070221A1
Authority
PE
Peru
Prior art keywords
hepatitis
virus
metoxyquinolin
diazatriciclo
iloxi
Prior art date
Application number
PE2006000917A
Other languages
English (en)
Inventor
Kenneth Simmen
Kock Herman De
Pierre Raboisson
Lili Hu
David Mcgowan
Dominique Surleraux
Abdellah Tahri
De Vreken Wim Van
Sandrine Vendeville
Original Assignee
Medivir Ab
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37036843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab, Tibotec Pharm Ltd filed Critical Medivir Ab
Publication of PE20070221A1 publication Critical patent/PE20070221A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE R1 ES ARILO O UN SISTEMA ANULAR SATURADO, PARCIALMENTE SATURADO O INSATURADO DE 5-6 MIEMBROS CON 1-3 HETEROATOMOS OPCIONALMENTE SUSTITUIDO; L ES UN ENLACE DIRECTO,-O-, -O-CO-,ENTRE OTRAS; R2 ES H, OR6, -C(=O)OR6, ENTRE OTRAS; R3 Y R4 SON CADA UNO H, ALQUILO C1-C6 O PUEDEN FORMAR UN ANILLO CICLOALQUILO C3-C7; n ES 3-6; R6 ES H, ALQUENILO C2-C6, CICLOALQUILO C3-C7 SUSTITUIDO CON ALQUILO C1-C6, ENTRE OTRAS. SON COMPUESTOS PREFERIDOS: ACIDO 18-[2-[4-(ISOPROPIL)TIAZOL-2-IL]-7-METOXIQUINOLIN-4-ILOXI]-2,15-DIOXO-3,16-DIAZATRICICLO[14,3,0,04,6]NONADEC-7-ENO-4-CARBOXILICO; N-[[18-[2-[2-(ISOPROPILAMINO)TIAZOL-4-IL]-7-METOXIQUINOLIN-4-ILOXI]-2,15-DIOXO-3,16-DIAZATRICICLO[14,3,0,046]NONADEC-7-ENO-4-CARBOXILICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS POSEEN ACTIVIDAD INHIBIDORA SOBRE LA REPLICACION DEL VIRUS DE HEPATITIS C, UTILES EN LA PREVENCION DE ENFERMEDADES HEPATICAS CRONICAS
PE2006000917A 2005-07-29 2006-07-26 Inhibidores macrociclicos del virus de la hepatitis c PE20070221A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107067 2005-07-29
EP05107413 2005-08-11

Publications (1)

Publication Number Publication Date
PE20070221A1 true PE20070221A1 (es) 2007-04-16

Family

ID=37036843

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000917A PE20070221A1 (es) 2005-07-29 2006-07-26 Inhibidores macrociclicos del virus de la hepatitis c

Country Status (27)

Country Link
US (1) US7989471B2 (es)
EP (1) EP1912995B1 (es)
JP (1) JP5426163B2 (es)
KR (1) KR101074673B1 (es)
CN (1) CN101233137B (es)
AP (1) AP2473A (es)
AR (1) AR055104A1 (es)
AT (1) ATE517902T1 (es)
AU (1) AU2006274858B2 (es)
BR (1) BRPI0614670A2 (es)
CA (1) CA2617095C (es)
DK (1) DK1912995T3 (es)
EA (1) EA014646B1 (es)
GT (1) GT200600341A (es)
IL (1) IL188283A (es)
JO (1) JO2768B1 (es)
MX (1) MX2008001395A (es)
MY (1) MY152153A (es)
NO (1) NO20081071L (es)
NZ (1) NZ564541A (es)
PE (1) PE20070221A1 (es)
SG (1) SG163613A1 (es)
SI (1) SI1912995T1 (es)
SV (1) SV2008002639A (es)
TW (1) TWI412534B (es)
UY (1) UY29705A1 (es)
WO (1) WO2007014919A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA200900969A1 (ru) * 2007-01-08 2010-02-26 Феномикс Корпорейшн Макроциклические ингибиторы протеазы гепатита с
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
MX2009008540A (es) * 2007-02-08 2009-08-18 Tibotec Pharm Ltd Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
MX2010005261A (es) 2007-11-14 2010-10-15 Enanta Pharm Inc Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010010276A (es) 2008-03-20 2011-03-25 Enanta Pharm Inc Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0922912A8 (pt) 2008-12-10 2018-01-02 Achillion Pharmaceuticals Inc peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2417134B1 (en) * 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN101987825B (zh) * 2009-07-31 2014-04-02 上海开拓者医药发展有限公司 一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104136453B (zh) * 2012-01-11 2018-01-12 艾伯维公司 用于制备hcv蛋白酶抑制剂的方法
CA2887621A1 (en) 2012-10-08 2014-04-17 Abbvie Inc. Compounds useful for making hcv protease inhibitors
SG11201502802PA (en) 2012-10-19 2015-05-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
JP2016515139A (ja) 2013-03-14 2016-05-26 アキリオン ファーマシューティカルズ，インコーポレーテッド ソバプレビルの新規の製造方法
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0727419B1 (en) 1992-12-29 2002-02-27 Abbott Laboratories Intermediates for the preparation of retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP0966465B1 (en) 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ES2405316T3 (es) 1999-03-19 2013-05-30 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima IMPDH
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA04009938A (es) * 2002-04-11 2004-12-13 Vertex Pharma Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv.
JP4733023B2 (ja) * 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c

Also Published As

Publication number Publication date
JP2009502882A (ja) 2009-01-29
UY29705A1 (es) 2007-05-31
NO20081071L (no) 2008-04-25
CN101233137B (zh) 2014-05-07
KR20080041651A (ko) 2008-05-13
WO2007014919A1 (en) 2007-02-08
KR101074673B1 (ko) 2011-10-19
MX2008001395A (es) 2008-04-16
NZ564541A (en) 2010-03-26
EA014646B1 (ru) 2010-12-30
EA200800484A1 (ru) 2008-06-30
CN101233137A (zh) 2008-07-30
CA2617095A1 (en) 2007-02-08
SV2008002639A (es) 2008-07-23
AU2006274858A1 (en) 2007-02-08
AU2006274858B2 (en) 2012-05-24
AP2473A (en) 2012-09-24
MY152153A (en) 2014-08-15
ATE517902T1 (de) 2011-08-15
JO2768B1 (en) 2014-03-15
EP1912995A1 (en) 2008-04-23
SI1912995T1 (sl) 2011-11-30
US20100240698A1 (en) 2010-09-23
SG163613A1 (en) 2010-08-30
HK1116772A1 (en) 2009-01-02
GT200600341A (es) 2007-02-26
EP1912995B1 (en) 2011-07-27
BRPI0614670A2 (pt) 2011-04-12
TW200745165A (en) 2007-12-16
DK1912995T3 (da) 2011-10-24
IL188283A0 (en) 2008-04-13
AR055104A1 (es) 2007-08-08
US7989471B2 (en) 2011-08-02
IL188283A (en) 2016-12-29
CA2617095C (en) 2014-05-13
JP5426163B2 (ja) 2014-02-26
TWI412534B (zh) 2013-10-21

Similar Documents

Publication Publication Date Title
PE20070221A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
MX2010006209A (es) Derivados de quinoxalinilo.
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
MX2010005262A (es) Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c.
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
EA201071034A1 (ru) Новые макроциклические ингибиторы репликаций вируса гепатита с
EA201290128A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
HRP20090459T1 (hr) Aminofenil derivati kao novi inhibitori histonskih deacetilaza
EA200602130A1 (ru) Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed